Skip to main content
Noul Co., Ltd. logo

Noul Co., Ltd. — Investor Relations & Filings

Ticker · 376930 ISIN · KR7376930004 KO Manufacturing
Open in API
Filings indexed 257 across all filing types
Latest filing 2026-03-13 Proxy Solicitation & In…
Country KR South Korea
Listing KO 376930

About Noul Co., Ltd.

https://noul.com/en/

Noul Co., Ltd. is a biotechnology company that develops innovative diagnostic solutions for blood and tissue analysis. The company's core product is the miLab™ platform, an all-in-one, fully automated medical device that integrates the entire diagnostic process from sample staining and digital imaging to artificial intelligence (AI)-powered analysis. This technology is designed to provide rapid and accurate diagnoses for blood-based diseases and cancer, with a focus on improving healthcare accessibility and diagnostic efficiency in various settings, including those with limited resources. Noul aims to address global health challenges by delivering advanced in-vitro and remote diagnostic capabilities.

Recent filings

Filing Released Lang Actions
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for the company 'Noul'. It outlines the date, location, agenda items (such as financial statement approval and director appointments), and details regarding the meeting. This type of document is a standard proxy solicitation or notice of meeting sent to shareholders to inform them of the upcoming AGM and request their participation/votes. Given the specific category 'Proxy Solicitation & Information Statement' (PSI), it fits perfectly as it provides the necessary information for shareholders to exercise their voting rights.
2026-03-13 Korean
[기재정정]주식매수선택권부여에관한신고
Regulatory Filings Classification · 95% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and specifically functions as a '정정신고' (Amendment Report). It details changes to previously reported stock option grants, including adjustments to exercise prices and the number of shares due to capital changes (rights offerings/bonus issues). As this is a specific regulatory disclosure regarding capital structure and equity-based compensation, and does not fit into the other specific categories like 'Director's Dealing' or 'Share Issue', it is classified as a Regulatory Filing (RNS).
2026-03-13 Korean
[기재정정]주식매수선택권부여에관한신고
Regulatory Filings Classification · 95% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and specifically identifies itself as a '정정신고' (Correction Report). It details changes to stock option grants, including adjustments to exercise prices and quantities due to capital changes (rights offerings). This type of disclosure regarding stock options and capital structure adjustments falls under general regulatory filings for corporate actions that do not fit into specific categories like M&A or dividends.
2026-03-13 Korean
[기재정정]주식매수선택권부여에관한신고
Regulatory Filings Classification · 95% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and specifically a '정정신고' (Amendment Report). It details changes to previously reported stock option grants, including adjustments to exercise prices and the number of shares due to capital changes (rights offerings). This type of disclosure regarding stock options and capital structure changes falls under the category of regulatory filings for corporate actions that do not fit into specific financial reporting categories like 10-K or ER.
2026-03-13 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 95% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and specifically identifies itself as a '정정신고' (Amendment Report). It details changes to previously reported stock option grants, including adjustments to the number of shares, exercise prices, and beneficiary details due to corporate actions like capital increases. This type of disclosure regarding stock-based compensation and capital structure changes falls under the category of regulatory filings for corporate actions.
2026-03-13 Korean
[기재정정]주식매수선택권부여에관한신고
Regulatory Filings Classification · 95% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and specifically marked as a '정정신고' (Amendment Report). It details changes to stock option grants, including adjustments to exercise prices and the number of shares due to capital changes (rights offering). This type of disclosure regarding stock option grants and their subsequent amendments falls under general regulatory filings as it does not fit into specific categories like director dealings or dividend announcements.
2026-03-13 Korean

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.